Tags
pharma expert
strategic advisor
merger and acquisitions
investment banker
angel investor
valuations
drug in licensing
drug out-license
due diligence
global pharma consultants
deal maker
pharmal consultants
private equity
venture capital
angel investors
bio-similar landscape
product and portfolio divestment
para iv opportunities
valuation
merger and acquisition opportunity
otc
fund raising
in-licensing and out licensing
product selection
portfolio prioritization
pharma consulting
eli lilly
pfizer
global pharmaceutical & biotechnology outlook 2014
novo nordisk
outlook 2014
glaxosmithkline
novartis
roche
bristol-myers squibb
astrazeneca
merck
prostate cancer
actemra
myrbetriq
dainnipon
daiichi sankyo
nhi price cut
kadcyla
biosimilar
perjeta
isavuconazole
japan generic opportunity
xtandi
ranbaxy
edoxaban
mpdl3280a
breast cancer
astellas
dainnipon sumitomo
chugai
prograf
cadila healthcare
dr. reddy's
ipca
shilpa medicare
biocon
sun pharma
shahsun pharma
natco
lupin
wockhardt
cipla
ambi
glpg
pharmacyclics
ambit bioscience
morphosys
basilea
isis pharma
incyte
endocyte
basl
ablx
enanata
ecyt
cemp
onconova
ablynx
enta
symbio
galapagos
cempra
japan generic presence in global market
japan generics
pharmaceutical & biotech industry expert
post excl. competition
settlement
innovator
litigation outcome
patent reissue
ftf vs innovator
para iv plus
non ftf vs innovator
citizen\'s petition
withdrawal
Mehr anzeigen
Präsentationen
(5)Dokumente
(2)Tags
pharma expert
strategic advisor
merger and acquisitions
investment banker
angel investor
valuations
drug in licensing
drug out-license
due diligence
global pharma consultants
deal maker
pharmal consultants
private equity
venture capital
angel investors
bio-similar landscape
product and portfolio divestment
para iv opportunities
valuation
merger and acquisition opportunity
otc
fund raising
in-licensing and out licensing
product selection
portfolio prioritization
pharma consulting
eli lilly
pfizer
global pharmaceutical & biotechnology outlook 2014
novo nordisk
outlook 2014
glaxosmithkline
novartis
roche
bristol-myers squibb
astrazeneca
merck
prostate cancer
actemra
myrbetriq
dainnipon
daiichi sankyo
nhi price cut
kadcyla
biosimilar
perjeta
isavuconazole
japan generic opportunity
xtandi
ranbaxy
edoxaban
mpdl3280a
breast cancer
astellas
dainnipon sumitomo
chugai
prograf
cadila healthcare
dr. reddy's
ipca
shilpa medicare
biocon
sun pharma
shahsun pharma
natco
lupin
wockhardt
cipla
ambi
glpg
pharmacyclics
ambit bioscience
morphosys
basilea
isis pharma
incyte
endocyte
basl
ablx
enanata
ecyt
cemp
onconova
ablynx
enta
symbio
galapagos
cempra
japan generic presence in global market
japan generics
pharmaceutical & biotech industry expert
post excl. competition
settlement
innovator
litigation outcome
patent reissue
ftf vs innovator
para iv plus
non ftf vs innovator
citizen\'s petition
withdrawal
Mehr anzeigen